LLY

920.62

+0.75%↑

JNJ

237.87

+0.33%↑

ABBV

205.74

-1.15%↓

NVS

148.69

-1.04%↓

AZN

189.45

+0.34%↑

LLY

920.62

+0.75%↑

JNJ

237.87

+0.33%↑

ABBV

205.74

-1.15%↓

NVS

148.69

-1.04%↓

AZN

189.45

+0.34%↑

LLY

920.62

+0.75%↑

JNJ

237.87

+0.33%↑

ABBV

205.74

-1.15%↓

NVS

148.69

-1.04%↓

AZN

189.45

+0.34%↑

LLY

920.62

+0.75%↑

JNJ

237.87

+0.33%↑

ABBV

205.74

-1.15%↓

NVS

148.69

-1.04%↓

AZN

189.45

+0.34%↑

LLY

920.62

+0.75%↑

JNJ

237.87

+0.33%↑

ABBV

205.74

-1.15%↓

NVS

148.69

-1.04%↓

AZN

189.45

+0.34%↑

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Atvērts

3.72 -1.06

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.62

Max

3.79

Galvenie mērījumi
By Trading Economics
Ienākumi	466K -27M
Pārdošana	2M 15M
Peļņas marža	-178.834
Darbinieki	141
EBITDA	-2M -29M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+274.23% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	29M 257M
Iepriekšējā atvēršanas cena	4.78
Iepriekšējā slēgšanas cena	3.72

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. marts 22:51 UTC

Peļņas

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

2026. g. 18. marts 21:40 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

2026. g. 18. marts 20:31 UTC

Peļņas

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

2026. g. 18. marts 23:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

2026. g. 18. marts 23:31 UTC

Tirgus saruna

Gold Rises on Likely Technical Recovery -- Market Talk

2026. g. 18. marts 22:49 UTC

Tirgus saruna

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

2026. g. 18. marts 22:41 UTC

Tirgus saruna

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

2026. g. 18. marts 22:36 UTC

Peļņas

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

2026. g. 18. marts 22:24 UTC

Peļņas

AIA Group Announces New Share Buyback of $1.7B >1299.HK

2026. g. 18. marts 22:23 UTC

Peļņas

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

2026. g. 18. marts 22:23 UTC

Peļņas

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

2026. g. 18. marts 21:58 UTC

Peļņas

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

2026. g. 18. marts 21:55 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2026. g. 18. marts 21:55 UTC

Tirgus saruna

Peļņas

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

2026. g. 18. marts 21:40 UTC

Tirgus saruna

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

2026. g. 18. marts 21:16 UTC

Tirgus saruna

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

2026. g. 18. marts 21:00 UTC

Galvenie ziņu notikumi

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

2026. g. 18. marts 20:58 UTC

Peļņas

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

2026. g. 18. marts 20:41 UTC

Peļņas

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026. g. 18. marts 20:29 UTC

Peļņas

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026. g. 18. marts 20:25 UTC

Peļņas

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026. g. 18. marts 20:17 UTC

Peļņas

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

2026. g. 18. marts 20:14 UTC

Tirgus saruna

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

2026. g. 18. marts 20:09 UTC

Peļņas

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

2026. g. 18. marts 20:07 UTC

Peļņas

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

2026. g. 18. marts 20:06 UTC

Peļņas

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

2026. g. 18. marts 20:04 UTC

Peļņas

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

2026. g. 18. marts 20:04 UTC

Peļņas

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

2026. g. 18. marts 20:04 UTC

Peļņas

Micron Technology Sees 3Q Gross Margin About 81% >MU

2026. g. 18. marts 20:03 UTC

Peļņas

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

274.23% augšup

Prognoze 12 mēnešiem

Vidējais 14.67 USD 274.23%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.